In mouse models of tumor growth, we found that the use of GSK-3 inhibitors such as SB415286 resulted in a reduction in tumor growth comparable to the effects of anti-PD-1 therapy in both B16 melanoma and EL4 lymphoma models [58]. This evidence concerns the gene PDCD1 and neoplasm.